Kovaltry is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) for adults, adolescents and children of all ages.
PTP, previously treated patient
*Patient years of exposure = International Units sold/annual dose per patient